Paper Details
- Home
- Paper Details
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Author: ChenShinn-Cherng, ChengTzu-Sheng, ChuangWan-Long, DaiChia-Yen, HsiehPing-Hsin, HuangChing-I, HuangChung-Feng, HuangJee-Fu, LiangPo-Cheng, LinZu-Yau, YehMing-Lun, YuMing-Lung
Original Abstract of the Article :
Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long-term outcomes. Several direct-acting antiviral agents (DAAs), including sofosbuvir (SOF) plus different NS5A inhibitors, as well as non...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1002/kjm2.12315
データ提供：米国国立医学図書館（NLM）
Real-World Effectiveness of Direct-Acting Antiviral Agents for Chronic Hepatitis C Patients
The field of [hepatitis C treatment] is constantly evolving, with new [direct-acting antiviral agents (DAAs)] offering hope for patients. This research, conducted in [Taiwan], focused on assessing the real-world efficacy of various DAA regimens in patients with [chronic hepatitis C (CHC) genotype-2 (GT-2)]. It's like exploring a vast desert, where each oasis represents a different treatment option, and we're searching for the most effective one.
The researchers employed a [retrospective study design] to examine the effectiveness of [SOF-based DAAs or GLE/PIB] in a large cohort of patients. They found that [the overall sustained virological response (SVR) rate was 97.9%], which is a very encouraging outcome. However, they also noticed that [the SVR rate was significantly lower in the SOF + RBV group (95.6%) than in the non-SOF + RBV (98.9%) group]. This highlights the importance of considering individual factors when choosing a treatment plan.
The Importance of Personalized Treatment Plans
The study emphasizes the need for [personalized treatment plans] based on the patient's [age, hepatitis B virus coinfection, baseline cirrhosis, or those who received SOF + RBV]. This is akin to tailoring a camel saddle to fit the individual camel - each patient's needs are unique.
The Potential of DAAs in Treating CHC GT-2
The findings suggest that [DAAs like SOF in combination with DCV, LDV, or VEL, as well as GLE/PIB] hold great promise for treating [CHC GT-2 patients]. This is a significant step forward in the fight against [hepatitis C], offering hope for a future where this debilitating disease is less prevalent.
Dr.Camel's Conclusion
This study adds to the growing body of evidence supporting the effectiveness of [DAAs] in treating [CHC GT-2]. However, it's crucial to recognize that [individual patient characteristics] can significantly impact treatment outcomes. As with navigating a vast desert, choosing the right path requires careful consideration and a tailored approach.
Date :
- Date Completed 2021-11-29
- Date Revised 2021-11-29
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.